Jupiter Endovascular raised $21M in new financing led by Sonder Capital to fund a pivotal trial for Pulmonary Embolism.
Jupiter Endovascular raised $21M in new financing led by Sonder Capital to fund a pivotal trial for Pulmonary Embolism.
08/15/24, 2:24 PM
Location
menlo parkMoney raised
$21 million
Industry
medical device
medical
biotechnology
health care
Investors
Sonder Capital
Jupiter Endovascular has exited stealth mode with a $21 million round of financing. The funding will support the company's upcoming pivotal trial for Pulmonary Embolism and further development of its Endoportal ControlTM technology.
Company Info
Location
menlo park, california, united states
Additional Info
Jupiter Endovascular is a medical technology startup developing the “endoportal procedure,” a new class of endovascular interventions using Endoportal Control to bring the precision and control of direct surgical access to catheter-based therapies. The procedure uses an endoportal device that navigates flexibly through the vasculature via percutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point.